Venus Remedies Limited has announced a significant internal restructuring within its promoter group. Two promoter entities, Sunev Pharma Solutions Private Limited ("Sunev") and Spine Software Systems Private Limited ("Spine"), have received board approval for a Scheme of Amalgamation. This scheme will see Sunev merge with and into Spine, subject to all necessary statutory and regulatory approvals. Sunev currently holds a substantial 17.21% of Venus Remedies Limited's equity share capital. Upon the successful completion of the amalgamation scheme, this stake will be transferred to Spine. The company has emphasized that this is an internal restructuring initiative among the promoter group entities and will not result in any change in the control of Venus Remedies Limited. Consequently, the aggregate shareholding of the promoter and promoter group in the company will remain unchanged. The announcement was made on March 2, 2026, in compliance with Regulation 30 of SEBI (LODR) Regulations, 2015. Venus Remedies Limited itself is not a direct party to this amalgamation scheme.
